Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...

Organogenesis (ORGO) announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a ...

Organogenesis (NASDAQ: ORGO) Q3 2024 Earnings Call Nov 12, 2024, 5:00 p.m. ET ...

As discussed in Catalyst, Organogenesis planned an imminent boost to its sports medicine revenues with its ReNu product in development: On 05/02/2024 Organogenesis reported that its phase 3 study ...

Organogenesis is a regenerative medicine company with an advanced wound care niche, and it's looking to take over a manufacturing site in Rhode Island. A Boston-based biotechnology firm could be ...

As the U.S. stock market navigates the uncertainty surrounding the presidential election and upcoming Federal Reserve interest rate decisions, investors are keeping a close eye on various sectors for ...

Organogenesis Stock Performance Organogenesis stock opened at $3.28 on Friday. The company’s 50-day moving average price is $2.90 and its 200-day moving average price is $2.78. The company has a ...

Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study ...

Organogenesis is the process by which the internal organs and specific structures such as the limb are formed during development of an organism. Organogenesis involves the coordination of multiple ...